<DOC>
	<DOCNO>NCT00572377</DOCNO>
	<brief_summary>Female sexual arousal disorder ( FSAD ) frequent find woman middle age prevalent post-menopausal woman . Topical alprostadil currently development treatment FSAD . The purpose research determine formula alprostadil safe effective woman FSAD . We compare alprostadil placebo . Each participant treat 1 month active alprostadil 1 month placebo without know use . This way , investigator compare effect alprostadil effect inactive topical gel . Post-menopausal woman FSAD recruit . The woman interested participate study first meet investigator answer question make sure eligible study fit diagnosis FSAD . Once enrol , subject fill questionnaires medical history , social history , psychosocial history . They also undergo medical examination . At introductory research visit fill baseline questionnaire , give medical history , undergo physical exam blood drawn . The informed consent review sign participant time . The subject return 1st treatment visit time vital sign like blood pressure heart rate take , external genitalia examine study drug dispense randomly assign either alprostadil placebo . After instruction , subject use first dose clinic monitor 2 hour look change vital sign local genitalia reaction . If problem note , subject send home study drug Female Sexual Encounter Profile Cards ( FSEP ) . The patient fill card sexual encounter . After 1 week patient contact phone ask side effect concern . After 4 week subject return another study visit time FSEP card leave study drug collect , questionnaire fill , labs drawn subject undergo exam external genitalia . The subject send home 2 week washout period . The subject return 2 week period study medication ; return process repeat either alprostadil placebo ( whichever receive first time ) .</brief_summary>
	<brief_title>Alprostadil ( FemLife Gel ) Treatment Female Sexual Arousal Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Sexual Dysfunction , Physiological</mesh_term>
	<mesh_term>Alprostadil</mesh_term>
	<criteria>1 . FSAD base American Foundation Urological Disease Consensus Panel definition 2 . Postmenopausal WISE criterion proof bilateral oophorectomy . 3 . FSAD least 6 month . 4 . History self report normal sexual arousal and/or orgasm past . 5 . Documentation normal PAP smear pelvic exam within past year . 6 . Women may hormone replacement therapy nonhormonal therapy . 1 . Primary anorgasmia , vaginismus , sexual pain sexual arousal disorder . 2 . History unresolved sexual trauma abuse . 3 . Endocrine disorder 4 . Chronic UTI , vaginal infection , pelvic inflammatory disease , dyspareunia within precede 12 month . 5 . STI 6 . Clinically significant renal , hepatic , neurologic , cardiac disease precede 6 month . 7 . Male partner impotence . 8 . Depression mood disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Sexual</keyword>
	<keyword>Arousal</keyword>
	<keyword>Female</keyword>
</DOC>